AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04421807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex decongestive therapy (CDT)
Description: In the treatment phase of CDT, manual lymph drainage, skin care, compression bandage, draining exercise were applied 5 days a week for 3 weeks. Compression socks, self-drainage, skin care and unloading exercises were applied for 5 weeks in the protection phase of CDT. Thus, patients were followed up with the CDT program for 8 weeks.
Study NCT01958112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212 (trametinib)
Description: Trametinib dose is 1.5 mg orally once per day
Study NCT01958112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: The dose of GSK2141795 is 50 mg orally once per day
Study NCT01085500 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mastery Learning TEP Curriculum
Description: A simulation-based educational curriculum
Study NCT01085500 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Current Practice
Description: The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
Study NCT01513369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric carboxymaltose
Description: Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
Study NCT01513369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (0,9%)
Description: Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
Study NCT03052933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level+0), or 60 mg/dose (level+1) of copanlisib. Maximal tolerated dose will be determined by modified 3+3 design including level-1 dose de-escalation.~For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study.
Study NCT03052933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,000 mg/m2 on Days 1 and 8 of each 28-day treatment cycle until maximum 6 cycles.
Study NCT00730262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLN-4601
Description: 14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
Study NCT00230477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepsera
Study NCT00230477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepsera and lamivudine
Study NCT01326559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, 5-FU and Cetuximab
Description: Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)
Study NCT02096575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrous oxide administration
Description: All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.~NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.~All patients will get local anesthesia via a standardized PCB.
Study NCT02862600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
Study NCT02862600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of bioanalytical assay to monitor plasma levels of perhexiline
Description: The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycofenolate mofetil
Description: 15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
Study NCT04418583 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Three-dimensional imaging
Description: Three-dimensional surface images, acquired by the Artec Leo
Study NCT03827148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical Care
Description: Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
Study NCT01010217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery > 1000/mcl.
Study NCT01439711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Study NCT01439711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT01439711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT05212493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis oil
Description: Cannabis oil 20:1 CBD:THC ratio
Study NCT03428750 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EN3835
Description: Collagenase clostridium histolyticum
Study NCT03428750 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04184024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Soft tissue massage known as Swedish massage technique was applied to the neck area for 20 minutes. This massage was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.
Study NCT04184024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio tape
Description: Patients were taped according to the Kenzo Kase's Kinesio Taping Method by an experienced physical therapist. The application was carried out in a relaxed sitting position. Y banding with extensor muscles on the back of the neck with muscle technique, I banding with the upper trapezius with muscle technique and I banding with ligament technique to the middle region of the neck were performed.
Study NCT04184024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck stabilization exercise
Description: Neck stabilization exercise was performed in stages with gradual progression according to the stages of motor learning and sensory-motor integration, namely, static, dynamic, and functional. The program started with postural training and then the cervical bracing technique with the activation of deep neck flexors for NSE was performed. The patients were asked to maintain a neutral spine during the exercises and throughout the day as much as possible. The difficulty and variety of exercises were increased weekly. It was carried out 3 days a week for 4 weeks (12 sessions) by the supervisor physiotherapist.
Study NCT03295006 — intervention group
Intervention type: DEVICE
Intervention: TheraSphere
Description: Patients who had received TheraSphere
Study NCT03550729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Endurance training 3 times per week during 3 months using interval training above 70% of load peak reached in the incremental exercise test. The duration of the sessions will be adapted individually to each patient (approximately 60 minutes).
Study NCT04590326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5668
Description: REGN5668 will be administered by once weekly intravenous (IV) infusion.
Study NCT04590326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: For Module 1, after a minimum of a 3-week monotherapy lead-in of REGN5668, cemiplimab will be administered concomitantly every 3 weeks (Q3W) by IV infusion.
Study NCT04590326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN4018
Description: For Module 2, a 4-5 week monotherapy lead-in of REGN4018 will be administered by once weekly IV infusion. After lead-in, REGN5668 and REGN4018 will be administered concomitantly.
Study NCT04590326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Administered by IV infusion as prophylaxis for mitigating potential CRS in patients receiving REGN4018
Study NCT01531140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol +Bisacodyl
Description: Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
Study NCT01531140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Description: Polyethylene glycol p.o.: 60 ml/kg/days
Study NCT01531140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sennosides
Description: Sennosides 1tbl/8kg for 2 days
Study NCT01699893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unique arm
Description: blood, nasal swab, skin biopsy, stool samples
Study NCT02153294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low tidal volume
Description: Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
Study NCT02153294 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: high tidal volume
Description: Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
Study NCT05463627 — intervention group
Intervention type: DRUG
Intervention: Metformin
Description: All participants among the three groups were treated with metformin
Study NCT01780493 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The Direct Nipple Ureteroneocystostomy Technique
Study NCT01121640 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: CA125 assay on Abbott Architect i1000SR platform
Description: Bead-based sandwich ELISA style assay
Study NCT03838848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: 3mg/kg, Q2W, intravenous injection (IV)
Study NCT01121640 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: HE4 assay on Architect i1000SR platform
Description: Bead-based sandwich ELISA style assay
Study NCT01121640 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transvaginal Ultrasound
Description: Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interval training day 1
Study NCT03838848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: 5mg/kg, Q2W, intravenous injection (IV)
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: interval training day 1
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interval training day 1
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate exercise day 2
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate exercise day 2
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate exercise day 2
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control day 3
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control day 3
Study NCT01474408 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control day 3
Study NCT02509351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: 400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
Study NCT02509351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placeboo
Description: women will recive 2 identical tablets as placeboo
Study NCT03141528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-learning
Description: Training without supervision
Study NCT03141528 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instructor-led learning
Description: Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
Study NCT00669747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin i.d. Days 1 & 15
Description: Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 \& 15
Study NCT00669747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin i.d. Day 1; Normal Saline i.d. Day 15
Description: Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
Study NCT00669747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline, 10 ml, i.d. on Days 1 and 15
Study NCT04280926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Troponin Testing
Description: Fresh serum or lithium heparin plasma samples will be measured with the Atellica IM TnIH assay (Siemens Heatlhineers).
Study NCT03838848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: 5mg/kg, Q3W, intravenous injection (IV)
Study NCT04436107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg administered orally twice daily (BID)
Study NCT04436107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Administered as specified in the treatment arm
Study NCT04006717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser therapy
Description: Diode laser (EPIC™ BIOLASE) with wavelength 940nm
Study NCT04006717 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low Level Laser therapy
Description: Diode laser (EPIC™ BIOLASE) with wavelength 940nm
Study NCT00453388 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo allogeneic bone marrow transplant
Study NCT00453388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT00453388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO
Study NCT00453388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT03954938 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Craving Manipulation
Description: Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
Study NCT03954938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving Manipulation
Description: Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
Study NCT03954938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
Study NCT03954938 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
Study NCT03954938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
Study NCT03954938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
Study NCT03954938 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
Study NCT03954938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
Study NCT02542579 — intervention group
Intervention type: GENETIC
Intervention: 16S rRNA pyrosequencing analysis
Description: Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
Study NCT03390400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecondlaser-assisted
Description: Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.
Study NCT03390400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior Capsulotomy
Description: Cataract Surgery
Study NCT03390400 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lens Fragmentation
Description: Cataract Surgery
Study NCT02531711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet A
Description: Experimental analgesic dietary intervention
Study NCT02531711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet B
Description: Healthy comparator diet
Study NCT01862965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PredEver
Description: Firstline treatment with prednisone and Everolimus
Study NCT03990337 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasonography of cricoid cartilage.
Study NCT02258919 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC) and best medical treatment
Description: Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
Study NCT02258919 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best medical treatment
Description: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
Study NCT05285163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: palliative care educatiom
Description: The patients in the intervention group were presented palliative care training in addition to their usual care
Study NCT03375307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT03375307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT04006717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra canal Cryotherapy
Description: Irrigation with cold saline 2-4 C
Study NCT00453388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00453388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT02638064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgiflo injection
Description: Curettage of sinus cavity then injection of surgiflo material
Study NCT03838848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 IV Q3W; total dose calculated according to the Calvert formula, with the highest dose not exceeding 750 mg; 4 cycles.
Study NCT03838848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, Q3W, intravenous injection (IV)
Study NCT03838848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningetinib
Description: Oral, QD
Study NCT00501852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: single-dose dry-powder inhaler (SDDPI)
Study NCT00501852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-dose dry-powder inhaler (SDDPI)
Study NCT00501852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: Handihaler inhaler
Study NCT00638846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A toric
Description: silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)